SEARCH

SEARCH BY CITATION

References

  • 1
    Munoz JJ, Ellison LM. Upper tract urothelial neoplasms: incidence and survival during the last 2 decades. J Urol. 2000; 164: 1523- 1525.
  • 2
    Mazeman E. Tumours of the upper urinary tract calyces, renal pelvis and ureter. Eur Urol. 1976; 2: 120- 126.
  • 3
    Babaian RJ, Johnson DE. Primary carcinoma of the ureter. J Urol. 1980; 123: 357- 359.
  • 4
    Sagalowsky AI, Jarrett TW. Management of urothelial tumors of the renal pelvis and ureter. In: WalshPC, RetikAB, VaughanEDJr, WeinAJ, eds. Campbell's Urology. 8th ed. Vol 4. Philadelphia: Saunders; 2002: 2845- 2875.
  • 5
    Harrell FE. Regression Modeling Strategies. New York: Springer-Verlag; 2001.
  • 6
    Rubin DB. Multiple Imputation for Nonresponse in Surveys. 1st ed. Vol 1. New York: John Wiley & Sons; 1987.
  • 7
    Pintilie M. Competing Risks: A Practical Perspective. Hoboken, NJ: John Wiley & Sons; 2006.
  • 8
    Therneau TM, Grambsch PM. Modeling Survival Data: Extending the Cox Model. New York: Springer; 2000.
  • 9
    Hall MC, Womack S, Sagalowsky AI, Carmody T, Erickstad MD, Roehrborn CG. Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: a 30-year experience in 252 patients. Urology. 1998; 52: 594- 601.
  • 10
    Huben RP, Mounzer AM, Murphy GP. Tumor grade and stage as prognostic variables in upper tract urothelial tumors. Cancer. 1988; 62: 2016- 2020.
  • 11
    Booth CM, Cameron KM, Pugh RC. Urothelial carcinoma of the kidney and ureter. Br J Urol. 1980; 52: 430- 435.
  • 12
    Ozsahin M, Zouhair A, Villa S, et al. Prognostic factors in urothelial renal pelvis and ureter tumours: a multicentre Rare Cancer Network study. Eur J Cancer. 1999; 35: 738- 743.
  • 13
    Corrado F, Ferri C, Mannini D, et al. Transitional cell carcinoma of the upper urinary tract: evaluation of prognostic factors by histopathology and flow cytometric analysis. J Urol. 1991; 145: 1159- 1163.
  • 14
    Wagle DG, Moore RH, Murphy GP. Primary carcinoma of the renal pelvis. Cancer. 1974; 33: 1642- 1648.
  • 15
    Williams CB, Mitchell JP. Carcinoma of the renal pelvis: a review of 43 cases. Br J Urol. 1973; 45: 370- 376.
  • 16
    Cummings KB, Correa RJJr, Gibbons RP, Stoll HM, Wheelis RF, Mason JT. Renal pelvic tumors. J Urol. 1975; 113: 158- 162.
  • 17
    Johansson S, Wahlqvist L. A prognostic study of urothelial renal pelvic tumors: comparison between the prognosis of patients treated with intrafascial nephrectomy and perifascial nephroureterectomy. Cancer. 1979; 43: 2525- 2531.
  • 18
    Mills C, Vaughan EDJr. Carcinoma of the ureter: natural history, management and 5-year survival. J Urol. 1983; 129: 275- 277.
  • 19
    Strobel SL, Jasper WS, Gogate SA, Sharma HM. Primary carcinoma of the renal pelvis and ureter. Evaluation of clinical and pathologic features. Arch Pathol Lab Med. 1984; 108: 697- 700.
  • 20
    Cozad SC, Smalley SR, Austenfeld M, Noble M, Jennings S, Raymond R. Transitional cell carcinoma of the renal pelvis or ureter: patterns of failure. Urology. 1995; 46: 796- 800.
  • 21
    Akaza H, Koiso K, Niijima T. Clinical evaluation of urothelial tumors of the renal pelvis and ureter based on a new classification system. Cancer. 1987; 59: 1369- 1375.
  • 22
    Charbit L, Gendreau MC, Mee S, Cukier J. Tumors of the upper urinary tract: 10 years of experience. J Urol. 1991; 146: 1243- 1246.
  • 23
    Miyao N, Masumori N, Takahashi A, et al. Lymph node metastasis in patients with carcinomas of the renal pelvis and ureter. Eur Urol. 1998; 33: 180- 185.
  • 24
    Corrado F, Mannini D, Ferri C, et al. The prognostic significance of DNA ploidy pattern in transitional cell cancer of the renal pelvis and ureter: continuing follow-up. Eur Urol. 1992; 21( suppl 1): 48- 50.
  • 25
    Keeley FXJr, Bibbo M, Bagley DH. Ureteroscopic treatment and surveillance of upper urinary tract transitional cell carcinoma. J Urol. 1997; 157: 1560- 1565.
  • 26
    Mullerad M, Russo P, Golijanin D, et al. Bladder cancer as a prognostic factor for upper tract transitional cell carcinoma. J Urol. 2004; 172( 6 pt 1): 2177- 2181.
  • 27
    Nakada T, Umeda K, Koike H, Akiya T, Katayama T. Clinical analysis of ureteral tumours with or without renal pelvic neoplasms. Int Urol Nephrol. 1987; 19: 377- 384.
  • 28
    Advanced Bladder Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet. 2003; 361: 1927- 1934.
  • 29
    Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003; 349: 859- 866.
  • 30
    Czito B, Zietman A, Kaufman D, Skowronski U, Shipley W. Adjuvant radiotherapy with and without concurrent chemotherapy for locally advanced transitional cell carcinoma of the renal pelvis and ureter. J Urol. 2004; 172( 4 pt 1): 1271- 1275.
  • 31
    Brookland RK, Richter MP. The postoperative irradiation of transitional cell carcinoma of the renal pelvis and ureter. J Urol. 1985; 133: 952- 955.
  • 32
    Maulard-Durdux C, Dufour B, Hennequin C, et al. Postoperative radiation therapy in 26 patients with invasive transitional cell carcinoma of the upper urinary tract: no impact on survival? J Urol. 1996; 155: 115- 117.
  • 33
    Bamias A, Deliveliotis C, Fountzilas G, et al. Adjuvant chemotherapy with paclitaxel and carboplatin in patients with advanced carcinoma of the upper urinary tract: a study by the Hellenic Cooperative Oncology Group. J Clin Oncol. 2004; 22: 2150- 2154.
  • 34
    Matsumura K, Sugimura K, Uchida J, Naganuma T, Nakatani T. Advanced ureteral cancer with complete remission achieved by taxan containing systemic chemotherapy. Int J Urol. 2003; 10: 105- 107.
  • 35
    Suzuki S, Shinohara N, Harabayashi T, Sato S, Abe T, Koyanagi T. Impact of adjuvant systemic chemotherapy on postoperative survival in patients with high-risk urothelial cancer. Int J Urol. 2004; 11: 456- 460.
  • 36
    Hosmer DW, Lemeshow S. Applied Survival Analysis: Regression Modeling of Time to Event Data. 1st ed. New York: Wiley-Interscience; 1999.
  • 37
    Murphy DM, Zincke H, Furlow WL. Primary grade 1 transitional cell carcinoma of the renal pelvis and ureter. J Urol. 1980; 123: 629- 631.
  • 38
    Lee BR, Jabbour ME, Marshall FF, Smith AD, Jarrett TW. 13-year survival comparison of percutaneous and open nephroureterectomy approaches for management of transitional cell carcinoma of renal collecting system: equivalent outcomes. J Endourol. 1999; 13: 289- 294.
  • 39
    Elliott DS, Blute ML, Patterson DE, Bergstralh EJ, Segura JW. Long-term follow-up of endoscopically treated upper urinary tract transitional cell carcinoma. Urology. 1996; 47: 819- 825.
  • 40
    Jabbour ME, Desgrandschamps F, Cazin S, Teillac P, Le Duc A, Smith AD. Percutaneous management of grade II upper urinary tract transitional cell carcinoma: the long-term outcome. J Urol. 2000; 163: 1105- 1107.
  • 41
    Iborra I, Solsona E, Casanova J, Ricos JV, Rubio J, Climent MA. Conservative elective treatment of upper urinary tract tumors: a multivariate analysis of prognostic factors for recurrence and progression. J Urol. 2003; 169: 82- 85.
  • 42
    Goel MC, Mahendra V, Roberts JG. Percutaneous management of renal pelvic urothelial tumors: long-term followup. J Urol. 2003; 169: 925- 929, discussion 929-930.